Novolog (Pharm UP 1966) Ltd.

As of June 30, 2026, Novolog (Pharm UP 1966) Ltd. carries a market capitalization of 38.21B, placing it among publicly traded companies globally. Its enterprise value stands at 35.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Novolog (Pharm UP 1966) Ltd. has 510.87M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.21, and the price-to-book ratio stands at 1.09.

As of June 30, 2026, Novolog (Pharm UP 1966) Ltd. trades at an EV/EBITDA multiple of 3.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.79 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 35.50B versus a market cap of 38.21B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Novolog (Pharm UP 1966) Ltd. maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.94, indicating elevated leverage, while an interest coverage ratio of 4.47 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Novolog (Pharm UP 1966) Ltd. posted a negative return on equity (ROE) of -0.19, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -17.84, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -0.02, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -13.80, pointing to unprofitable operations over the period. The company generates approximately 197.02M in revenue per employee across its workforce of 921.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.80 indicates how many times Novolog (Pharm UP 1966) Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novolog (Pharm UP 1966) Ltd. recorded 202.00M in income tax expense. That works out to an effective tax rate of 403.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 50.10M, leaving -67.40M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Novolog (Pharm UP 1966) Ltd.'s stock has declined approximately 30.50% over the past 52 weeks. The 50-day moving average sits at 79.58, while the 200-day moving average is 95.04.

Over the twelve months ended June 30, 2026, Novolog (Pharm UP 1966) Ltd. generated 181.45B in revenue and converted that into -67.40M in net income, yielding earnings per share of -0.12. EBITDA reached 11.18B, while operating income came in at 3.29B.

As of June 30, 2026, Novolog (Pharm UP 1966) Ltd. holds 20.45B in cash and equivalents against 17.12B in total debt, resulting in a net debt position of -20.45B. Total book value stands at 35.09B, with working capital of -12.76B providing operational flexibility.

Novolog (Pharm UP 1966) Ltd. produced 8.90B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.40B in capital expenditures, free cash flow totaled 3.50B - equivalent to 6.85 per share.

Over the twelve months ended June 30, 2026, Novolog (Pharm UP 1966) Ltd. posted a gross margin of 7.61, reflecting its pricing power and cost economics. The operating margin of 1.81 and net profit margin of -0.04 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Novolog (Pharm UP 1966) Ltd. paid dividends of 3.91 per share. The dividend payout ratio of -3,508.77 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.16, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 19.72, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Novolog (Pharm UP 1966) Ltd. shareholders.